A newly approved drug treats severe hot flashes caused by menopause by blocking specific signals in the brain, rather than using hormones like estrogen, the U.S. Food and Drug Administration (FDA) announced Friday (May 12).
The pill, called Veozah (generic name fezolinetant), is the first of its kind approved to treat menopausal hot flashes. Known as a "neurokinin 3 (NK3) receptor antagonist," the drug effectively blocks NK3 receptors found in a part of the brain called the hypothalamus, an almond-size structure that regulates the body's hormone production and temperature, among other functions.
